Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4013)	12/8/2015 11:55:05 AM
From: civic08801	Respond to of 4474

Thanks again Jaybe for all that you contribute. If you were on the Scientific Advisory Committee for a BP trying to assess ARIA as a buyout what would you recommend re the trials success and the IP etc ?

To: jaybe who wrote (4013)	12/8/2015 12:51:45 PM
From: mulanoon2007	Read Replies (1) \| Respond to of 4474

In justification of the phase III and dose-range finding trials earlier in the year Dr Clackson mentioned the attraction of early activity/efficacy read-out by biomarkers. i.e. landmark time-points are well described for NIL (and other 2GTKIs) with the 3-month time-point being predictive of later land-mark time-points (and indeed long-term PFS). An update of biomarkers at the three-month landmark time-point is not inconceivable, is it? Early termination for futility would reduce the cost of trial failure but beat up PPS. My prejudice is that ARIA know enough to have confidence in safety and comparative efficacy. But I think Biomaven's point on whether this is the best use of cash is good.